Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
154.74B
Market cap154.74B
Price-Earnings ratio
20.01
Price-Earnings ratio20.01
Dividend yield
6.32%
Dividend yield6.32%
Average volume
60.84M
Average volume60.84M
High today
$27.37
High today$27.37
Low today
$26.40
Low today$26.40
Open price
$26.67
Open price$26.67
Volume
50.69M
Volume50.69M
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 154.74B, Pfizer(PFE) trades at $27.15. The stock has a price-to-earnings ratio of 20.01 and currently yields dividends of 6.3%.

During the trading session on 2026-02-08, Pfizer(PFE) shares reached a daily high of $27.37 and a low of $26.40. At a current price of $27.15, the stock is +2.8% higher than the low and still -0.8% under the high.

Trading volume for Pfizer(PFE) stock has reached 50.69M, versus its average volume of 60.84M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

Simply Wall St 13h
Assessing Pfizer Valuation After New PF-3944 Obesity Trial Data And Market Reentry

Pfizer (PFE) is back in the obesity spotlight after reporting Phase 2b VESPER-3 data for its monthly GLP-1 injection, PF-3944, showing up to 12.3% placebo adjus...

Assessing Pfizer Valuation After New PF-3944 Obesity Trial Data And Market Reentry
Simply Wall St 2d
Is Pfizer Offering Value After Recent Share Price Rebound

If you are wondering whether Pfizer is genuinely good value or just looks cheap on the surface, this article walks through what the current numbers are really s...

Is Pfizer Offering Value After Recent Share Price Rebound
TipRanks 2d
Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults: What Investors Should Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer is running an early-stage clinical trial titled “An Interventional...

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

TipRanks 2d
Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Advances Mid-Stage Trial of New Obesity Drug PF-07976016 Study Overview: This Pha...

TipRanks 2d
H.C. Wainwright says Chantix news ‘significant win’ for Achieve Life Sciences

H.C. Wainwright views Pfizer’s (PFE) launch of Chantix among the 30 medicines it placed on the White House’s direct-to-consumer site, TrumpRx, as “a significant...

TipRanks 2d
Trump Trade: Argentina says U.S. to cut hundreds of tariffs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump...

Seeking Alpha 2d
Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for it...

Pfizer wins FDA priority review for Hympavzi label expansion
TipRanks 2d
Pfizer says FDA grants Priority Review for sBLA for Hympavzi

Pfizer (PFE) announced that the U.S. FDA has accepted and granted Priority Review for the company’s supplemental Biologics License Application for Hympavzi to e...

Nasdaq 3d
Pfizer Launches TrumpRx Program To Expand Affordable Access To Medicines Across U.S.

(RTTNews) - Pfizer Inc. (PFE) announced the launch of its TrumpRx program, designed to make innovative medicines more affordable and accessible to millions of A...

Pfizer Launches TrumpRx Program To Expand Affordable Access To Medicines Across U.S.
TipRanks 3d
Pfizer launches program on TrumpRx to make medicines ‘more affordable’

Pfizer (PFE) said it “announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Start...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.